Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

Inclusion Criteria: * Patients must have a histologically confirmed diagnosis of symptomatic multiple myeloma with evaluable disease parameters * A diagnosis of symptomatic multiple myeloma requires: * A monoclonal serum and/or urine protein * Clonal bone marrow plasmacytosis, or a histologically confirmed plasmacytoma * Related organ or tissue impairment, consisting of: * Hypercalcemia (serum calcium \> 0.25 mmol/l above the upper limit of normal, or \> 2.75 mmol/l \[i.e. \> 11.5 mg/dl\]) AND/OR * Renal insufficiency (serum creatinine \> 173 mmol/l \[i.e., \> 2 mg/dL\]); (please note that serum creatinine may not be \>= 2.5 mg/dL) AND/OR * Anemia (hemoglobin 2 g/dl below the lower limit of normal, or hemoglobin \< 10 g/dl) AND/OR * Bony lesions (lytic bony lesions, or osteoporosis with compression fractures) AND/OR * Other findings, such as symptomatic hyperviscosity, amyloidosis, or recurring bacterial infections (\> 2 episodes in 12 months) * Patients may not have undergone any prior therapy, with the following exceptions: * Prior plasmapheresis with plasma exchange (PLEX) for a hyperviscosity syndrome is allowed, providing the patient has no current evidence of hyperviscosity and has not required PLEX for at least one week prior to initiation of therapy * Prior radiation therapy to areas of spinal cord compression by plasmacytomas, painful lesions due to bony involvement, or other myeloma-related indications, is allowed provided that radi…